Dr. Kamdar has served as a member of Evofem Biosciences’ board of directors since January 2018. Dr. Kamdar is a Managing Partner of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005 and a Managing Partner of Medical Excellence Capital, LLC, since 2021.
Dr. Kamdar is current Chair of the board of directors of Seraphina Therapeutics, Inc., and Truvian Sciences. She also serves on the board of directors of Sera Prognostics (Nasdaq: SERA), Alume, Trotana, Recellience15, Pleno, and Savanna Biotherapeutics. Past investments include Ariosa (acquired by Roche), Corthera (acquired by Novartis), BiPar Sciences (acquire by Sanofi-Aventis) and Omniome (acquired by NASDAQ: PACB).
Formerly, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to joining MPM, She was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents. Dr. Kamdar received her B.A. from Northwestern University and Ph.D. in biochemistry and genetics from Emory University.
Dr. Kamdar serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and is on the board of the La Jolla Institute of Immunology.